Company news

OncoSil Medical Ltd news

Latest news releases, newest first. Pick a year for every news release, call and deck from that year.

View company

Positive Preliminary Results from PANCOSIL Phase 1-2 Study

September 17, 2025

Appendix 4E and Annual Report

August 29, 2025

Completion of Recruitment in TRIPP-FFX Clinical Trial

July 22, 2025

Completion of Recruitment in PANCOSIL Study

July 3, 2025

OSL announces $8.7m capital raise to drive commercialisation

May 26, 2025

Consolidation/Split - OSL

May 1, 2025

120 German Hospitals entitled to negotiate fee for OncoSil

February 3, 2025

OncoSil Medical Receives MDR Approval

January 27, 2025

OncoSil receives $1.05m R&D tax incentive

January 8, 2025

Oncosil completes $1 million Share Purchase Plan (SPP)

December 12, 2024

Prospectus 2024 Share Purchase Plan (SPP) Offer

November 5, 2024

OSL completes $7 M Placement and announces $1 M SPP

October 27, 2024

G-BA Approval received for OncoSil Device

October 23, 2024

Appendix 4E Preliminary Financial Report

August 29, 2024

Successful Treatment with OncoSil Device in Turkiye

August 15, 2024

Australian institution to invest $2.7 million in OSL

July 24, 2024

$5.3 million raised under Entitlement Offer

May 2, 2024

1st Study in Man Increases Pancreatic Tumor Vascularity

April 30, 2024

First patient treated with OncoSil device in Turkiye

April 15, 2024

First patient treated in the UK for the TRIPP-FXX study

April 11, 2024

First Austria-based treatments utilising the OncoSil device

April 4, 2024

Prospectus - Entitlement Offer

March 24, 2024

Placement and Entitlement Offer to raise up to $7.1 million

March 19, 2024

84 German hospitals can negotiate fee for Oncosil device

January 31, 2024

OncoSil receives $1.1m R&D tax incentive

December 14, 2023

First two commercial patient treatments in Greece

December 7, 2023

OncoSil onboards first patient in PANCOSIL Clinical Trial

November 28, 2023

Multi-Centre Data on OncoSil in Metastatic Pancreatic Cancer

June 30, 2023

Ethics Committee Approves PANCOSIL Clinical Trial

June 4, 2023

First patient treatment in Italy

May 21, 2023

First patient enrolled in the TRIPP-FFX Clinical Study

May 2, 2023

OncoSil to streamline operating structure

May 1, 2023

First year anniversary of the OSPREY post-marketing registry

April 30, 2023

Oral presentation at The Mayo Clinic IMPACT Course

April 23, 2023

Further commercial milestones achieved in Spain

April 23, 2023

Additional Binding Commitment Received for Entitlement Offer

April 21, 2023

Non-renounceable Rights Issue Offer Prospectus

March 19, 2023

Commitment received for Offer and updated Timetable

March 17, 2023

Entitlement Offer Presentation

March 16, 2023

Entitlement Offer to raise up to $9.9 million

March 16, 2023

Half-Yearly Report Results

February 28, 2023

Half Yearly Report and Accounts

February 28, 2023

Two key treatment centres treat first patients with OncoSil

January 30, 2023

OncoSil achieves milestone of 10 patients treated in Spain

December 14, 2022

Distribution agreement signed for selected Chinese markets

December 13, 2022

2022 AGM CEO Presentation

October 25, 2022

OncoSil Receives $832k R&D Tax Incentive

October 23, 2022

OncoSil to Present at South-West Connect ASX Showcase

October 17, 2022

Appendix 4E Announcement

August 30, 2022

Investor Presentation

August 3, 2022

← Newer news releases · Older news releases →

Decks

The 5 newest of 41 decks. Every deck is listed under its year.